CervoMed (CRVO) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 11, 2017
Document Information [Line Items]
Entity Registrant Name	Diffusion Pharmaceuticals Inc.
Entity Central Index Key	1,053,691
Trading Symbol	dffn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		14,022,120
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 7,413,399	$ 1,552,852
Certificate of deposit	10,000,000
Prepaid expenses, deposits and other current assets	287,893	50,844
Total current assets	17,701,292	1,603,696
Property and equipment, net	479,650	79,755
Intangible asset	8,639,000	8,639,000
Goodwill	6,929,258	6,929,258
Other assets	157,229	232,675
Total assets	33,906,429	17,484,384
Current liabilities:
Current portion of convertible debt	2,430,000	1,880,000
Accounts payable	1,039,002	1,684,158
Accrued expenses and other current liabilities	1,232,696	874,264
Common stock warrant liability	24,757,670
Total current liabilities	29,459,368	4,438,422
Convertible debt, net of current portion		550,000
Deferred income taxes	3,279,363	3,279,363
Other liabilities		31,915
Total liabilities	32,738,731	8,299,700
Commitments and Contingencies
Preferred stock	0	0
Stockholders’ Equity:
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 12,247,984 and 10,345,637 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	12,299	10,346
Additional paid-in capital	69,596,807	69,363,575
Accumulated deficit	(68,441,408)	(60,189,237)
Total stockholders' equity	1,167,698	9,184,684
Total liabilities, convertible preferred stock and stockholders' equity	$ 33,906,429	$ 17,484,384

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0
Preferred stock, shares authorized (in shares)	13,750,000	0
Preferred stock, shares issued (in shares)	12,376,329	0
Preferred stock, shares outstanding (in shares)	10,498,843	0
Preferred stock, liquidation value	$ 21,207,478	$ 0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	12,247,984	10,345,637
Common stock, shares outstanding (in shares)	12,247,984	10,345,637

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating expenses:
Research and development	$ 1,179,544	$ 1,444,906	$ 2,187,115	$ 3,797,713
General and administrative	1,795,886	2,349,227	3,349,025	6,211,711
Depreciation	5,790	5,845	12,393	13,698
Loss from operations	2,981,220	3,799,978	5,548,533	10,023,122
Other expense (income):
Interest expense, net	18,889	6,216	74,608	6,237
Change in fair value of warrant liability (Note 10)	(23,387,850)		(10,468,176)
Warrant related expenses (Note 7)			10,225,846
Other financing expenses			2,870,226
Net income (loss)	$ 20,387,741	$ (3,806,194)	$ (8,251,037)	$ (10,029,359)
Per share information:
Net income (loss) per share of common stock, basic (in dollars per share)	$ 0.88	$ (0.37)	$ (0.83)	$ (0.99)
Net income (loss) per share of common stock, diluted (in dollars per share)	$ (1)	$ (0.37)	$ (1.56)	$ (0.99)
Weighted average shares outstanding, basic (in shares)	10,828,063	10,263,703	10,582,521	10,130,042
Weighted average shares outstanding, diluted (in shares)	13,872,632	10,263,703	12,339,386	10,130,042

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($)		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2016		10,345,637
Balance at Dec. 31, 2016		$ 10,346	$ 69,363,575	$ (60,189,237)			$ 9,184,684
Sale of Series A convertible preferred stock and common stock warrants (in shares)		25,735			12,376,329
Series A cumulative preferred dividend			(546,305)			$ (546,305)	(546,305)
Conversion of accrued dividends related to convertible preferred stock		$ 26	70,864				70,890
Conversion of Series A convertible preferred stock to common stock (in shares)		1,926,991			(1,926,991)
Conversion of Series A convertible preferred stock to common stock		$ 1,927	(1,927)
Beneficial conversion feature for accrued interest of convertible debt			28,017				28,017
Stock-based compensation expense			681,449				681,449
Net loss				(8,251,037)			(8,251,037)
Balance (in shares) at Jun. 30, 2017		12,298,363			10,449,338
Balance at Jun. 30, 2017		$ 12,299	69,596,807	(68,441,408)			$ 1,167,698
Cumulative effect of change in accounting principle (a)	[1]		$ 1,134	$ (1,134)
[1]	In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of this standard.

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities:
Net loss	$ (8,251,037)	$ (10,029,359)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12,393	13,698
Loss on sale or disposal of assets		6,761
Stock-based compensation expense	681,449	731,633
Common stock issued for advisory services		1,409,363
Warrant related expense, change in fair value, and other financing expenses	2,627,896
Non-cash interest expense	85,309	4,754
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(68,189)	17,712
Accounts payable, accrued expenses and other liabilities	(1,249,735)	356,124
Net cash used in operating activities	(6,161,914)	(7,489,314)
Cash flows (used in) provided by investing activities:
Purchases of property and equipment	(64,002)	(2,331)
Purchase of certificate of deposit	(10,000,000)
Cash received in reverse merger transaction		8,500,602
Net cash (used in) provided by investing activities	(10,064,002)	8,498,271
Cash flows provided by financing activities:
Proceeds from the sale of Series A convertible preferred stock and warrants, net	22,129,774
Payment of offering costs for Series B convertible preferred stock	(43,311)
Net cash provided by financing activities	22,086,463
Net increase in cash and cash equivalents	5,860,547	1,008,957
Cash and cash equivalents at beginning of period	1,552,852	1,997,192
Cash and cash equivalents at end of period	7,413,399	3,006,149
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued expenses	(348,286)
Series B offering costs in accounts payable and accrued expenses	(50,103)
Series A cumulative preferred dividends	(546,305)
Conversion of accrued dividends related to convertible preferred stock	70,890
Conversion of convertible notes and related accrued interest into common stock		711,495
Consideration in connection with RestorGenex Corporation merger transaction		21,261,000
Series A Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Series A cumulative preferred dividends	(546,305)
Convertible Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Conversion of accrued dividends related to convertible preferred stock	$ 70,890

Note 1 - Organization and Descr

Note 1 - Organization and Description of Business	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization and Description of Business Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), a Delaware corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, trans sodium crocetinate (“TSC”) for use in many cancer types in which tumor oxygen deprivation ("hypoxia") is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. At an End-Of-Phase 2 3 On January 8, 2016, January 1, 2016 January 7, 2016

Note 2 - Liquidity

Note 2 - Liquidity	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity The Company has not No The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third March 2017, $25.0 one one 12,376,329 $22.1 $2.9 1,179,558 As disclosed in the Company's definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission (“SEC”) on May 1, 2017, $20.0 $0.001 $2.10 one 5 one $2.31. June 15, 2017. no The Company currently does not may May 26, 2017, not 5550 2 $35.0 30 not 5550 1 $2.5 5550 3 two three The Company has 180 November 20, 2017, third may not The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company’s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company’s product candidates become approved drugs and the extent of their market share. The regulatory approval and market acceptance of the Company’s proposed future products (if any), length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company believes its cash and cash equivalents and certificate of deposit at June 30, 2017 March 2018.

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Basis of Presentation and Summary of Significant Accounting Policies The Summary of Significant Accounting Policies included in the Company's Form 10 December 31, 2016, March 31, 2017 not Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X June 30, 2017, three six June 30, 2017 2016 six June 30, 2017 2016. six June 30, 2017 not may December 31, 2017. not December 31, 2016 10 March 31, 2017. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may Cash and Cash Equivalents and Certificate of Deposit The Company considers any highly liquid investments, such as money market funds, with an original maturity of three three one Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, certificate of deposit, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of each of June 30, 2017 December 31, 2016, $2.6 3 Offering Costs Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company’s private placement financings and are recognized in other assets on the consolidated balance sheet. At June 30, 2017 December 31, 2016, $93,000 $0.2 Intangible Assets and Goodwill In connection with the Merger, the Company acquired indefinite-lived In-Process Research and Development Assets (“IPR&D”) RES- 529 440, $8.6 $1.0 $6.9 third 2016, 440 $0. 529 October 1 no 529 three six June 30, 2017. Net Income (Loss) Per Common Share For the three June 30, 2017, two may two not no Diluted net income (loss) per common share is computed under the two two For the periods in which the Company reported a net loss, there was no two three June 30, 2017, two For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include stock options, unvested restricted stock awards and warrants using the treasury stock method. The diluted loss per common share calculation is also affected by the assumed exercise of the liability classified warrants using the treasury stock method, if dilutive, and adjusting the numerator for the change in fair value of the warrant liability. In addition, the Company considers the potential dilutive impact of its convertible debt instruments using the "if-converted" method. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Basic net income (loss) per common share calculation: Net income (loss) $ 20,387,741 $ (3,806,194 ) $ (8,251,037 ) $ (10,029,359 ) Accretion of Series A cumulative preferred dividends (487,460 ) — (546,305 ) — Undistributed earnings allocated to participating securities (10,416,153 ) — — — Net income (loss) attributable to common stockholders $ 9,484,128 (3,806,194 ) (8,797,342 ) (10,029,359 ) Weighted average shares outstanding, basic 10,828,063 10,263,703 10,582,521 10,130,042 Net income (loss) per share of common stock, basic $ 0.88 $ (0.37 ) $ (0.83 ) $ (0.99 ) Diluted net income (loss) per common share calculation: Net income (loss) attributable to common stockholders $ 9,484,128 (3,806,194 ) (8,797,342 ) (10,029,359 ) Change in fair value of warrant liability (23,387,850 ) — (10,468,176 ) — Diluted net loss $ (13,903,722 ) (3,806,194 ) (19,265,518 ) (10,029,359 ) Weighted average shares outstanding, basic 10,828,063 10,263,703 10,582,521 10,130,042 Shares from dilutive warrants 3,044,569 — 1,756,865 — Weighted average shares outstanding, diluted 13,872,632 10,263,703 12,339,386 10,130,042 Net income (loss) per share of common stock, diluted $ (1.00 ) $ (0.37 ) $ (1.56 ) $ (0.99 ) The following potentially dilutive securities outstanding as of June 30, 2017 2016 June 30, 2017 2016 Convertible debt 774,886 429,161 Convertible preferred stock 10,449,338 — Common stock warrants 457,721 461,209 Stock options 2,525,989 1,797,812 Unvested restricted stock awards 6,132 12,273 14,214,066 2,700,455 Amounts in the table reflect the common stock equivalents of the noted instruments. Recent Accounting Pronouncements In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 first second December 15, 2018 In May 2017, No. 2017 09, Modification Accounting for Share-Based Payment Arrangements 718. not December 15, 2017 not In March 2016, 2016 09, Compensation – Improvements to Employee Share-Based Payment Accounting December 15, 2016 2017 2016 09, $1,000 January 1, 2017. In February 2016, 2016 02, Leases (Topic 842 December 15, 2018,

Note 4 - Acquisition

Note 4 - Acquisition	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. Acquisition Reverse Merger with RestorGenex On January 8, 2016, The purchase price was calculated as follows: Fair value of RestorGenex shares outstanding $ 19,546,000 Estimated fair value of RestorGenex stock options outstanding 1,321,000 Estimated fair value of RestorGenex warrants outstanding 384,000 CVRs – RES-440 product candidate 10,000 Total purchase price $ 21,261,000 The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&D was the cost approach. The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date: Cash and cash equivalents $ 8,500,602 Prepaid expenses and other assets 195,200 Property and equipment 57,531 Intangible assets 9,600,000 Goodwill 6,929,258 Accrued liabilities (377,432 ) Deferred tax liability (3,644,159 ) Net assets acquired $ 21,261,000 Qualitative factors supporting the recognition of goodwill due to the Merger transaction include the Company’s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the reverse merger transaction to the Company’s later state product portfolio. The goodwill is not Pro Forma Financial Information (Unaudited) The following pro forma financial information reflects the condensed consolidated results of operations of the Company as if the acquisition of RestorGenex had taken place on January 1, 2016. not Six Months Ended June 30, 2016 Net revenues $ — Net loss (8,464,138 ) Basic and diluted loss per share $ (0.84 ) Non-recurring pro forma transaction costs directly attributable to the Merger were $1.6 six June 30, 2016 six June 30, 2016 $1.1 46,000 $0.5 January 8, 2016. $3.0 $2.7 six June 30, 2016. No three six June 30, 2017 three June 30, 2016.

Note 5 - Other Accrued Expenses

Note 5 - Other Accrued Expenses and Liabilities	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	5. Other Accrued Expenses and Liabilities Other accrued expenses and liabilities consisted of the following: June 30, 2017 December 31, 2016 Accrued interest payable $ 119,975 $ 29,359 Accrued Series A dividends 475,414 — Accrued payroll and payroll related expenses 251,465 399,740 Accrued professional fees 340,481 72,855 Accrued clinical studies expenses 27,071 220,978 Other accrued expenses 18,290 151,332 Total $ 1,232,696 $ 874,264

Note 6 - Convertible Debt

Note 6 - Convertible Debt	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Convertible Debt The following table provides the details of the convertible debt outstanding at June 30, 2017 December 31, 2016: Note Issue Date Maturity Date Conversion Price Interest Rate Total Principal 2016 Convertible Notes 9/27/2016 9/27/2017 $ 3.50 6.00 % $ 1,880,000 Series B Note 3/15/2011 6/30/2018 $ 2.74 1.00 % 550,000 Total principal amount $ 2,430,000 The accrued interest related to the Company’s Series B Convertible Note and 2016 June 30, 2017, $120,000.

Note 7 - Convertible Preferred

Note 7 - Convertible Preferred Stock and Common Stock Warrants	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. Convertible Preferred Stock and Common Stock Warrants In contemplation of completing the private placement described below, the Company amended and restated its articles of incorporation and authorized 13,750,000 not Series A Convertible Preferred Stock Transaction In March 2017, $25.0 one one 8.0% may, one $2.02 one $2.22, fifth The Company sold 12,376,329 $22.1 $2.9 1,179,558 $2.22 fifth During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC 815 40, Derivatives and Hedging, Contracts in an Entity’s own Equity 815 40” 815 40 not no As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are no $10.2 six June 30, 2017. Dividends The Company shall pay a cumulative preferential dividend on each share of the Series A convertible preferred stock outstanding at a rate of 8.0% April 1 October 1 October 1, 2017. not $0.5 three six June 30, 2017, Voting Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the “Certificate of Designation”) or as required by law, the holders of the Series A convertible preferred stock votes together with the holders of common stock as a single class on an adjusted as-converted basis. In accordance with NASDAQ listing rules, in any matter voted on by the holders of our common stock, each share of Series A convertible preferred stock entitles the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance of such shares of Series A convertible preferred stock. Accordingly, shares of Series A convertible preferred stock issued in the initial closing of the private placement on March 14, 2017 0.84874 March 31, 2017 0.50627 Liquidation Preference The Series A convertible preferred stock is senior to the common stock. In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A convertible preferred stock shall be entitled to receive their original investment amount. If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution shall be distributed ratably among the holders of the Series A convertible preferred stock in proportion to the full amounts to which they would otherwise be entitled. Conversion The Series A convertible preferred stock is convertible, at the holder’s option, into common stock. At the Company’s option, the Series A convertible preferred stock can be converted into common stock upon (a) the thirty $8.00 $10.0 Upon any conversion, any unpaid dividends shall be payable to the holders of Series A convertible preferred stock. During the three June 30, 2017, 1,926,991 $71,000 25,735 Make-Whole Provision Until March 2020 $10.0 $2.02 105% not Common Stock Warrants As of June 30, 2017, Outstanding Range of exercise price per share Common stock warrants issued prior to Merger 457,721 $20.00 - $750.00 Common stock warrants issued in Series A 13,555,887 $2.22 14,013,608 During the six June 30, 2017, 3,000 2019. March 2017 March 2022. three six June 30, 2017, $23.4 $2.6

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8. Stock-Based Compensation 2015 The Diffusion Pharmaceuticals Inc. 2015 "2015 January 1, 4.0% December 31, 413,825 January 1, 2017, may 2015 June 30, 2017, 134,291 2015 The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated: Three Months Ended June 30, Six Months Ended 2017 2016 2017 2016 Research and development $ 24,072 $ 184,051 $ 67,404 $ 426,328 General and administrative 290,994 154,111 614,045 305,305 Total stock-based compensation expense $ 315,066 $ 338,162 $ 681,449 $ 731,633 The following table summarizes the activity related to all stock option grants to employees and non-employees for the six June 30, 2017: Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Balance at January 1, 2017 2,207,409 $ 8.09 Granted 320,041 2.54 Expired (1,461 ) 15.00 Outstanding at June 30, 2017 2,525,989 $ 7.38 7.60 Exercisable at June 30, 2017 1,636,919 $ 8.80 6.74 Non-employee Stock Options Non-employee options are remeasured to fair value each period using a Black-Scholes option-pricing model until the options vest. During the six June 30, 2017, 9,394 three June 30, 2017 2016 $12,000 $0.2 six June 30, 2017 2016 $76,000 $0.5 June 30, 2017, 23,063 $48,000 1.76 Employee Stock Options During the six June 30, 2017, 310,647 $2.17 six June 30, 2017. three June 30, 2017 2016 $0.3 $0.1 six June 30, 2017 2016, $0.6 $0.2 No June 30, 2017, $3.1 5.3 Options granted were valued using the Black-Scholes model and the weighted average assumptions used to value the options granted during the first six 2017 Expected term (in years) 5.68 Risk-free interest rate 2.0 % Expected volatility 114.9 % Dividend yield — % Restricted Stock Awards As of June 30, 2017, 6,132 three June 30, 2017 2016, 1,533 1,533 $3,000 $3,000, six June 30, 2017 2016, 3,066 3,072 $6,000 $6,000, June 30, 2017, $12,000 1.0

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Office Space Rental The Company leases office and laboratory facilities in Charlottesville, Virginia. On March 31, 2017, three June 30, 2017, $0.4 three June 30, 2017 2016 $35,500 $17,000, six June 30, 2017 2016 $52,000 $33,000, May 1, 2017 April 30, 2022. not June 30, 2017 Rental Commitments 2017 $ 55,492 2018 112,354 2019 114,409 2020 116,464 2021 118,519 Thereafter 58,232 Total $ 575,470 Legal Proceedings On August 7, 2014, Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH No. BC553996 December 30, 2014, April 1, 2015, April 14, 2015, January 8, 2016, No may

Note 10 - Fair Value Measuremen

Note 10 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	10. Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one three first two • Level 1—Quoted • Level 2—Observable 1 not • Level 3—Unobservable no The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2017 (Level 1) (Level 2) (Level 3) Assets Cash and cash equivalents $ 7,413,399 $ — $ — Certificate of deposit $ 10,000,000 Liabilities Common stock warrant liability $ — $ — $ 24,757,670 December 31, 2016 (Level 1) (Level 2) (Level 3) Assets Cash and cash equivalents $ 1,552,852 $ — $ — The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Common Stock Warrant Liability Balance at December 31, 2016 $ — Issued in connection with the Series A convertible preferred stock 35,225,846 Change in fair value (10,468,176 ) Balance at June 30, 2017 $ 24,757,670 The common stock warrants issued in connection with the Series A convertible preferred stock are classified as liabilities on the accompanying balance sheet at June 30, 2017. June 30, 2017 Stock price $ 2.33 Exercise price $ 2.22 Expected term (in years) 4.75 Risk-free interest rate 1.9 % Expected volatility 110.0 % Dividend yield —

Note 11 - Subsequent Events

Note 11 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Event On July 5, 2017,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X June 30, 2017, three six June 30, 2017 2016 six June 30, 2017 2016. six June 30, 2017 not may December 31, 2017. not December 31, 2016 10 March 31, 2017.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents and Certificate of Deposit The Company considers any highly liquid investments, such as money market funds, with an original maturity of three three one
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, certificate of deposit, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of each of June 30, 2017 December 31, 2016, $2.6 3
Offering Costs, Policy [Policy Text Block]	Offering Costs Offering costs consist principally of legal costs incurred through the balance sheet date related to the Company’s private placement financings and are recognized in other assets on the consolidated balance sheet. At June 30, 2017 December 31, 2016, $93,000 $0.2
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill In connection with the Merger, the Company acquired indefinite-lived In-Process Research and Development Assets (“IPR&D”) RES- 529 440, $8.6 $1.0 $6.9 third 2016, 440 $0. 529 October 1 no 529 three six June 30, 2017.
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) Per Common Share For the three June 30, 2017, two may two not no Diluted net income (loss) per common share is computed under the two two For the periods in which the Company reported a net loss, there was no two three June 30, 2017, two For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include stock options, unvested restricted stock awards and warrants using the treasury stock method. The diluted loss per common share calculation is also affected by the assumed exercise of the liability classified warrants using the treasury stock method, if dilutive, and adjusting the numerator for the change in fair value of the warrant liability. In addition, the Company considers the potential dilutive impact of its convertible debt instruments using the "if-converted" method. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Basic net income (loss) per common share calculation: Net income (loss) $ 20,387,741 $ (3,806,194 ) $ (8,251,037 ) $ (10,029,359 ) Accretion of Series A cumulative preferred dividends (487,460 ) — (546,305 ) — Undistributed earnings allocated to participating securities (10,416,153 ) — — — Net income (loss) attributable to common stockholders $ 9,484,128 (3,806,194 ) (8,797,342 ) (10,029,359 ) Weighted average shares outstanding, basic 10,828,063 10,263,703 10,582,521 10,130,042 Net income (loss) per share of common stock, basic $ 0.88 $ (0.37 ) $ (0.83 ) $ (0.99 ) Diluted net income (loss) per common share calculation: Net income (loss) attributable to common stockholders $ 9,484,128 (3,806,194 ) (8,797,342 ) (10,029,359 ) Change in fair value of warrant liability (23,387,850 ) — (10,468,176 ) — Diluted net loss $ (13,903,722 ) (3,806,194 ) (19,265,518 ) (10,029,359 ) Weighted average shares outstanding, basic 10,828,063 10,263,703 10,582,521 10,130,042 Shares from dilutive warrants 3,044,569 — 1,756,865 — Weighted average shares outstanding, diluted 13,872,632 10,263,703 12,339,386 10,130,042 Net income (loss) per share of common stock, diluted $ (1.00 ) $ (0.37 ) $ (1.56 ) $ (0.99 ) The following potentially dilutive securities outstanding as of June 30, 2017 2016 June 30, 2017 2016 Convertible debt 774,886 429,161 Convertible preferred stock 10,449,338 — Common stock warrants 457,721 461,209 Stock options 2,525,989 1,797,812 Unvested restricted stock awards 6,132 12,273 14,214,066 2,700,455 Amounts in the table reflect the common stock equivalents of the noted instruments.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 first second December 15, 2018 In May 2017, No. 2017 09, Modification Accounting for Share-Based Payment Arrangements 718. not December 15, 2017 not In March 2016, 2016 09, Compensation – Improvements to Employee Share-Based Payment Accounting December 15, 2016 2017 2016 09, $1,000 January 1, 2017. In February 2016, 2016 02, Leases (Topic 842 December 15, 2018,

Note 3 - Basis of Presentatio19

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Basic net income (loss) per common share calculation: Net income (loss) $ 20,387,741 $ (3,806,194 ) $ (8,251,037 ) $ (10,029,359 ) Accretion of Series A cumulative preferred dividends (487,460 ) — (546,305 ) — Undistributed earnings allocated to participating securities (10,416,153 ) — — — Net income (loss) attributable to common stockholders $ 9,484,128 (3,806,194 ) (8,797,342 ) (10,029,359 ) Weighted average shares outstanding, basic 10,828,063 10,263,703 10,582,521 10,130,042 Net income (loss) per share of common stock, basic $ 0.88 $ (0.37 ) $ (0.83 ) $ (0.99 ) Diluted net income (loss) per common share calculation: Net income (loss) attributable to common stockholders $ 9,484,128 (3,806,194 ) (8,797,342 ) (10,029,359 ) Change in fair value of warrant liability (23,387,850 ) — (10,468,176 ) — Diluted net loss $ (13,903,722 ) (3,806,194 ) (19,265,518 ) (10,029,359 ) Weighted average shares outstanding, basic 10,828,063 10,263,703 10,582,521 10,130,042 Shares from dilutive warrants 3,044,569 — 1,756,865 — Weighted average shares outstanding, diluted 13,872,632 10,263,703 12,339,386 10,130,042 Net income (loss) per share of common stock, diluted $ (1.00 ) $ (0.37 ) $ (1.56 ) $ (0.99 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2017 2016 Convertible debt 774,886 429,161 Convertible preferred stock 10,449,338 — Common stock warrants 457,721 461,209 Stock options 2,525,989 1,797,812 Unvested restricted stock awards 6,132 12,273 14,214,066 2,700,455

Note 4 - Acquisition (Tables)

Note 4 - Acquisition (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Business Combination, Preliminary Purchase Price Consideration [Table Text Block]	Fair value of RestorGenex shares outstanding $ 19,546,000 Estimated fair value of RestorGenex stock options outstanding 1,321,000 Estimated fair value of RestorGenex warrants outstanding 384,000 CVRs – RES-440 product candidate 10,000 Total purchase price $ 21,261,000
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash and cash equivalents $ 8,500,602 Prepaid expenses and other assets 195,200 Property and equipment 57,531 Intangible assets 9,600,000 Goodwill 6,929,258 Accrued liabilities (377,432 ) Deferred tax liability (3,644,159 ) Net assets acquired $ 21,261,000
Business Acquisition, Pro Forma Information [Table Text Block]	Six Months Ended June 30, 2016 Net revenues $ — Net loss (8,464,138 ) Basic and diluted loss per share $ (0.84 )

Note 5 - Other Accrued Expens21

Note 5 - Other Accrued Expenses and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Other Current Liabilities [Table Text Block]	June 30, 2017 December 31, 2016 Accrued interest payable $ 119,975 $ 29,359 Accrued Series A dividends 475,414 — Accrued payroll and payroll related expenses 251,465 399,740 Accrued professional fees 340,481 72,855 Accrued clinical studies expenses 27,071 220,978 Other accrued expenses 18,290 151,332 Total $ 1,232,696 $ 874,264

Note 6 - Convertible Debt (Tabl

Note 6 - Convertible Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Convertible Debt [Table Text Block]	Note Issue Date Maturity Date Conversion Price Interest Rate Total Principal 2016 Convertible Notes 9/27/2016 9/27/2017 $ 3.50 6.00 % $ 1,880,000 Series B Note 3/15/2011 6/30/2018 $ 2.74 1.00 % 550,000 Total principal amount $ 2,430,000

Note 7 - Convertible Preferre23

Note 7 - Convertible Preferred Stock and Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block]	Outstanding Range of exercise price per share Common stock warrants issued prior to Merger 457,721 $20.00 - $750.00 Common stock warrants issued in Series A 13,555,887 $2.22 14,013,608

Note 8 - Stock-based Compensa24

Note 8 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended 2017 2016 2017 2016 Research and development $ 24,072 $ 184,051 $ 67,404 $ 426,328 General and administrative 290,994 154,111 614,045 305,305 Total stock-based compensation expense $ 315,066 $ 338,162 $ 681,449 $ 731,633
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Balance at January 1, 2017 2,207,409 $ 8.09 Granted 320,041 2.54 Expired (1,461 ) 15.00 Outstanding at June 30, 2017 2,525,989 $ 7.38 7.60 Exercisable at June 30, 2017 1,636,919 $ 8.80 6.74
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected term (in years) 5.68 Risk-free interest rate 2.0 % Expected volatility 114.9 % Dividend yield — %

Note 9 - Commitments and Cont25

Note 9 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Rental Commitments 2017 $ 55,492 2018 112,354 2019 114,409 2020 116,464 2021 118,519 Thereafter 58,232 Total $ 575,470

Note 10 - Fair Value Measurem26

Note 10 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	June 30, 2017 (Level 1) (Level 2) (Level 3) Assets Cash and cash equivalents $ 7,413,399 $ — $ — Certificate of deposit $ 10,000,000 Liabilities Common stock warrant liability $ — $ — $ 24,757,670 December 31, 2016 (Level 1) (Level 2) (Level 3) Assets Cash and cash equivalents $ 1,552,852 $ — $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Common Stock Warrant Liability Balance at December 31, 2016 $ — Issued in connection with the Series A convertible preferred stock 35,225,846 Change in fair value (10,468,176 ) Balance at June 30, 2017 $ 24,757,670
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Stock price $ 2.33 Exercise price $ 2.22 Expected term (in years) 4.75 Risk-free interest rate 1.9 % Expected volatility 110.0 % Dividend yield —

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	May 01, 2017	Mar. 31, 2017	Mar. 31, 2017	Jun. 30, 2017	Jan. 07, 2018
Class of Warrant or Right, Term				4 years 273 days
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.22
Series A Preferred Stock [Member] | Private Placement [Member]
Private Placement Proceeds, Gross			$ 25,000,000
Number of Convertible Preferred Stock Per Unit		1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1	1
Temporary Equity, Stock Issued During Period, New Issues			12,376,329
Private Placement Proceeds, Net			$ 22,100,000
Payments of Stock Issuance Costs			$ 2,900,000		$ 2,900,000
Class of Warrant or Right, Granted During Period			1,179,558
Series B Preferred Stock [Member]
Preferred Stock, Intended Par or Stated Value Per Share	$ 0.001
Preferred Stock, Intended Offering Price Per Share	$ 2.10
Number of Convertible Preferred Stock Per Unit	1
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Maximum Preferred Stock Intended to Be Offered, Value	$ 20,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.31

Note 3 - Basis of Presentatio28

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jan. 01, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 15, 2015
Impairment of Long-Lived Assets to be Disposed of	$ 0	$ 0
Deferred Offering Costs	93,000	93,000		$ 200,000
Intangible Assets, Net (Excluding Goodwill)					$ 0
Goodwill	6,929,258	6,929,258		6,929,258		$ 6,900,000
Accounting Standards Update 2016-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			$ 1,000
RES-529 [Member]
Intangible Assets, Net (Excluding Goodwill)						8,600,000
RES-440 [Member]
Intangible Assets, Net (Excluding Goodwill)						$ 1,000,000
Fair Value, Inputs, Level 3 [Member]
Convertible Debt, Fair Value Disclosures	$ 2,600,000	$ 2,600,000		$ 2,600,000

Note 3 - Basis of Presentatio29

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income (loss)	$ 20,387,741	$ (3,806,194)	$ (8,251,037)	$ (10,029,359)
Accretion of Series A cumulative preferred dividends	(487,460)		(546,305)
Undistributed earnings allocated to participating securities	(10,416,153)
Net income (loss) attributable to common stockholders	9,484,128	(3,806,194)	(8,797,342)	(10,029,359)
Net income (loss) attributable to common stockholders	9,484,128	(3,806,194)	(8,797,342)	(10,029,359)
Fair Value Adjustment of Warrants	(23,387,850)		(10,468,176)
Diluted net loss	$ (13,903,722)	$ (3,806,194)	$ (19,265,518)	$ (10,029,359)
Weighted average shares outstanding, basic (in shares)	10,828,063	10,263,703	10,582,521	10,130,042
Net income (loss) per share of common stock, basic (in dollars per share)	$ 0.88	$ (0.37)	$ (0.83)	$ (0.99)
Shares from dilutive warrants	$ 3,044,569		$ 1,756,865
Weighted average shares outstanding, diluted (in shares)	13,872,632	10,263,703	12,339,386	10,130,042
Net income (loss) per share of common stock, diluted (in dollars per share)	$ (1)	$ (0.37)	$ (1.56)	$ (0.99)

Note 3 - Basis of Presentatio30

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Anti-dilutive securities (in shares)	14,214,066	2,700,455
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)	774,886	429,161
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities (in shares)	10,449,338
Warrant [Member]
Anti-dilutive securities (in shares)	457,721	461,209
Employee Stock Option [Member]
Anti-dilutive securities (in shares)	2,525,989	1,797,812
Restricted Stock [Member]
Anti-dilutive securities (in shares)	6,132	12,273

Note 4 - Acquisition (Details T

Note 4 - Acquisition (Details Textual) - USD ($)	Jan. 08, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation				$ 681,449	$ 731,633
Executive Officers [Member]
Severance Costs	$ 3,000,000	$ 0	$ 0	0
Diffusion LLC [Member] | Employee Stock Option [Member]
Share-based Compensation	2,700,000	$ 0	$ 0	$ 0
Diffusion LLC [Member] | Success Fee Agreement Costs [Member]
Payments for Other Fees	$ 1,100,000
Stock Issued During Period, Shares, Issued for Services	46,000
Stock Issued During Period, Value, Issued for Services	$ 500,000
Diffusion LLC [Member] | Acquisition-related Costs [Member]
Business Combination, Acquisition Related Costs					$ 1,600,000

Note 4 - Acquisition - Purchase

Note 4 - Acquisition - Purchase Price Consideration (Details) - RestorGenex [Member] - Diffusion LLC [Member]	Jan. 08, 2016USD ($)
Fair value of RestorGenex shares outstanding	$ 19,546,000
Estimated fair value of RestorGenex stock options outstanding	1,321,000
Estimated fair value of RestorGenex warrants outstanding	384,000
CVRs – RES-440 product candidate	10,000
Total purchase price	$ 21,261,000

Note 4 - Acquisition - Summary

Note 4 - Acquisition - Summary of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jan. 08, 2016	Dec. 15, 2015
Goodwill	$ 6,929,258	$ 6,929,258		$ 6,900,000
Diffusion LLC [Member]
Cash and cash equivalents			$ 8,500,602
Prepaid expenses and other assets			195,200
Property and equipment			57,531
Intangible assets			9,600,000
Goodwill			6,929,258
Accrued liabilities			(377,432)
Deferred tax liability			(3,644,159)
Net assets acquired			$ 21,261,000

Note 4 - Acquisition - Pro Form

Note 4 - Acquisition - Pro Forma Financial Information (Details) - Diffusion LLC [Member]	6 Months Ended
	Jun. 30, 2016USD ($)$ / shares
Net revenues
Net loss	$ (8,464,138)
Basic and diluted loss per share (in dollars per share) | $ / shares	$ (0.84)

Note 5 - Accrued Expenses and L

Note 5 - Accrued Expenses and Liabilities - Summary of Accrued Expenses (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued interest payable	$ 119,975	$ 29,359
Accrued Series A dividends	475,414
Accrued payroll and payroll related expenses	251,465	399,740
Accrued professional fees	340,481	72,855
Accrued clinical studies expenses	27,071	220,978
Other accrued expenses	18,290	151,332
Total	$ 1,232,696	$ 874,264

Note 6 - Convertible Debt (Deta

Note 6 - Convertible Debt (Details Textual)	Jun. 30, 2017USD ($)
Interest Payable	$ 120,000

Note 6 - Convertible Debt - Out

Note 6 - Convertible Debt - Outstanding Convertible Notes (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / shares
Total principal amount	$ 2,430,000
2016 Convertible Notes [Member]
Maturity Date	Sep. 27, 2017
Conversion Price (in dollars per share) | $ / shares	$ 3.50
Interest Rate	6.00%
Total principal amount	$ 1,880,000
Issue Date	Sep. 27, 2016
Convertible Note Series B [Member]
Maturity Date	Jun. 30, 2018
Conversion Price (in dollars per share) | $ / shares	$ 2.74
Interest Rate	1.00%
Total principal amount	$ 550,000
Issue Date	Mar. 15, 2011

Note 7 - Convertible Preferre38

Note 7 - Convertible Preferred Stock and Common Stock Warrants (Details Textual)	May 01, 2017$ / sharesshares	Mar. 31, 2017$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / shares$ / itemshares	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)$ / shares$ / itemshares	Jun. 30, 2016USD ($)	Jan. 07, 2018USD ($)	Mar. 14, 2017$ / item
Stock Reclassified Upon Conversion of Preferred Stock						$ 70,890
Make-Whole Provision Conversion Price, Percentage						105.00%
Fair Value Adjustment of Warrants				$ (23,387,850)		$ (10,468,176)
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 2.22		$ 2.22
Class of Warrant or Right, Term						4 years 273 days
Warrant Expense						$ 10,225,846
Dividends						$ 546,305
Maximum [Member]
Convertible Preferred Stock, Conversion Price | shares				2.02		2.02
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 750		$ 750
Minimum [Member]
Financing Trigger from Issuance of Common Stock				$ 10,000,000		$ 10,000,000
Convertible Preferred Stock, Make-Whole Provision, Proceeds from Issue of Common Stock						$ 10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 20		$ 20
Warrant [Member]
Class of Warrant or Rights, Expired | shares						3,000
Warrant Expense				$ 2,600,000		$ 2,600,000
Private Placement [Member]
Convertible Preferred Stock, Votes Per Share | $ / item				0.50627		0.50627			0.84874
Private Placement [Member] | Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares		1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 2.22	$ 2.22
Class of Warrant or Right, Term		5 years
Warrant Expense						$ 10,200,000
Series A Preferred Stock [Member]
Conversion of Stock, Shares Converted | shares				1,926,991
Stock Reclassified Upon Conversion of Preferred Stock				$ 71,000
Stock Reclassified Upon Conversion of Preferred Stock, Shares | shares				25,735
Preferred Stock, Shares Authorized | shares				13,750,000		13,750,000
Fair Value Adjustment of Warrants				$ 23,400,000		$ 23,400,000
Proceeds from Issuance of Private Placement						0
Dividends						$ 546,305
Series A Preferred Stock [Member] | Maximum [Member]
Convertible Preferred Stock, Make-Whole Provision, Minimum Share Price | $ / shares						$ 8
Series A Preferred Stock [Member] | Private Placement [Member]
Private Placement Proceeds, Gross			$ 25,000,000
Number of Convertible Preferred Stock Per Unit | shares		1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares		1	1
Preferred Stock, Dividend Rate, Percentage		8.00%
Number of Common Stock Per Unit | shares		1
Convertible Preferred Stock, Conversion Price | shares		2.02	2.02
Temporary Equity, Stock Issued During Period, New Issues | shares			12,376,329
Private Placement Proceeds, Net			$ 22,100,000
Payments of Stock Issuance Costs			$ 2,900,000					$ 2,900,000
Class of Warrant or Right, Granted During Period | shares			1,179,558
Dividends				$ 500,000		$ 500,000
Series B Preferred Stock [Member]
Number of Convertible Preferred Stock Per Unit | shares	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares	1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.31
Class of Warrant or Right, Term	5 years
Series B Preferred Stock [Member] | Private Placement [Member] | Placement Agent [Member]
Class of Warrant or Right, Granted During Period | shares			1,179,558
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 2.22	$ 2.22
Class of Warrant or Right, Term		5 years

Note 7 - Convertible Preferre39

Note 7 - Convertible Preferred Stock and Common Stock Warrants - Warrants Outstanding to Acquire Shares of its Common Stock (Details)	Jun. 30, 2017$ / sharesshares
Common stock warrants, outstanding (in shares) | shares	14,013,608
Exercise price (in dollars per share) | $ / shares	$ 2.22
Minimum [Member]
Exercise price (in dollars per share) | $ / shares	20
Maximum [Member]
Exercise price (in dollars per share) | $ / shares	$ 750
Convertible Preferred Stock Issued Prior to Merger [Member]
Common stock warrants, outstanding (in shares) | shares	457,721
Series A Convertible Preferred Stock [Member]
Common stock warrants, outstanding (in shares) | shares	13,555,887

Note 8 - Stock-based Compensa40

Note 8 - Stock-based Compensation (Details Textual) - USD ($)	Jan. 01, 2017	Jul. 21, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Allocated Share-based Compensation Expense			$ 315,066	$ 338,162	$ 681,449	$ 731,633
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					320,041
Non-employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			23,063		23,063
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 48,000		$ 48,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 year 277 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					9,394
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			12,000	200,000	$ 76,000	500,000
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			3,100,000		$ 3,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 2.17
Allocated Share-based Compensation Expense			$ 300,000	$ 100,000	$ 600,000	$ 200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					5 years 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					310,647
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0	0	0	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number			6,132		6,132
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			1,533	1,533	3,066	3,072
Allocated Share-based Compensation Expense			$ 3,000	$ 3,000	$ 6,000	$ 6,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options			$ 12,000		$ 12,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 year
Restorgenex Corporation 2015 Equity Incentive Plan [Member]
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	413,825
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			134,291		134,291

Note 8 - Stock-based Compensa41

Note 8 - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Allocated Share-based Compensation Expense	$ 315,066	$ 338,162	$ 681,449	$ 731,633
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	24,072	184,051	67,404	426,328
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 290,994	$ 154,111	$ 614,045	$ 305,305

Note 8 - Stock-based Compensa42

Note 8 - Stock-based Compensation - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Balance at January 1, 2017 (in shares) | shares	2,207,409
Balance at January 1, 2017 (in dollars per share) | $ / shares	$ 8.09
Granted (in shares) | shares	320,041
Granted (in dollars per share) | $ / shares	$ 2.54
Expired (in shares) | shares	(1,461)
Expired (in dollars per share) | $ / shares	$ 15
Options outstanding, weighted-average per share exercise price (in dollars per share) | $ / shares	$ 7.38
Options outstanding, weighted-average remaining contractual life (Year)	7 years 219 days
Exercisable at June 30, 2017 (in shares) | shares	1,636,919
Exercisable at June 30, 2017 (in dollars per share) | $ / shares	$ 8.80
Exercisable at June 30, 2017 (Year)	6 years 270 days
Options outstanding (in shares) | shares	2,525,989

Note 8 - Stock-based Compensa43

Note 8 - Stock-based Compensation - Share-based Payment Award, Fair Value Assumptions (Details)	6 Months Ended
	Jun. 30, 2017
Dividend yield
Minimum [Member]
Expected term (in years) (Year)	5 years 248 days
Risk-free interest rate	2.00%
Expected volatility	114.90%

Note 9 - Commitments and Cont44

Note 9 - Commitments and Contingencies (Details Textual) - Charlottesville, Virginia [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Leasehold Improvements [Member]
Property, Plant and Equipment, Additions	$ 400,000
Building [Member]
Operating Leases, Rent Expense, Net	$ 35,500	$ 17,000	$ 52,000	$ 33,000

Note 9 - Commitments and Cont45

Note 9 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)	Jun. 30, 2017USD ($)
2,017	$ 55,492
2,018	112,354
2,019	114,409
2,020	116,464
2,021	118,519
Thereafter	58,232
Total	$ 575,470

Note 10 - Fair Value Measurem46

Note 10 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Certificate of deposit	$ 10,000,000
Common stock warrant liability	24,757,670
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Certificate of deposit	10,000,000
Common stock warrant liability
Cash and cash equivalents	7,413,399	$ 1,552,852
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Certificate of deposit
Common stock warrant liability
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Certificate of deposit
Common stock warrant liability	$ 24,757,670

Note 10 - Fair Value Measurem47

Note 10 - Fair Value Measurements - Reconciliation of Contingent Consideration Liability (Details) - Contingent Consideration [Member]	6 Months Ended
	Jun. 30, 2017USD ($)
Issued in connection with the Series A convertible preferred stock	$ 35,225,846
Change in fair value	(10,468,176)
Balance	$ 24,757,670

Note 10 - Fair Value Measurem48

Note 10 - Fair Value Measurements - Black -Scholes Model and Assumptions (Details)	6 Months Ended
	Jun. 30, 2017$ / shares
Stock price (in dollars per share)	$ 2.33
Exercise price (in dollars per share)	$ 2.22
Expected term (in years) (Year)	4 years 273 days
Risk-free interest rate	1.90%
Expected volatility	110.00%